New Data Released from CureVac COVID-19 Vaccine Trial

CureVac N.V. has experienced a 3% increase in its shares premarket on Friday following the release of new data from a trial of its mRNA COVID-19 vaccine candidates, developed in collaboration with GSK PLC. The investigational monovalent shot and bivalent vaccine candidate have successfully elevated antibody levels and demonstrated good tolerability across various dosages, according to CureVac's statement. Notably, all three dose levels tested were lower than those currently used in mRNA-based COVID vaccines approved in the U.S. and European Union. CureVac is currently engaged in advanced discussions with regulators to pave the way for a phase 3 study of the vaccine candidates. Should they receive approval, these shots would become competitors to mRNA Covid vaccines already available from Moderna Inc. and Pfizer Inc.

Over the past 12 months, CureVac shares have experienced a decline of 34%, while the S&P 500 has shown a gain of 23%. GSK's American depositary receipts also saw a premarket decline of 0.5% on Friday, but have achieved an increase of 13.3% over the past year.